company background image
NEU logo

Neuren Pharmaceuticals ASX:NEU Stock Report

Last Price

AU$19.31

Market Cap

AU$2.4b

7D

-0.4%

1Y

49.6%

Updated

13 Jun, 2024

Data

Company Financials +

Neuren Pharmaceuticals Limited

ASX:NEU Stock Report

Market Cap: AU$2.4b

NEU Stock Overview

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance6/6
Financial Health6/6
Dividends0/6

Neuren Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Neuren Pharmaceuticals
Historical stock prices
Current Share PriceAU$19.31
52 Week HighAU$25.95
52 Week LowAU$10.02
Beta2.03
1 Month Change-4.41%
3 Month Change-4.59%
1 Year Change49.57%
3 Year Change1,385.38%
5 Year Change1,639.64%
Change since IPO160.95%

Recent News & Updates

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31
Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03
Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

Recent updates

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31
Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03
Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05
Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02
Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18
Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02
Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31
Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31
Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03
We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19
Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04
Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Shareholder Returns

NEUAU PharmaceuticalsAU Market
7D-0.4%-0.6%-0.7%
1Y49.6%53.6%8.2%

Return vs Industry: NEU underperformed the Australian Pharmaceuticals industry which returned 53.6% over the past year.

Return vs Market: NEU exceeded the Australian Market which returned 8.2% over the past year.

Price Volatility

Is NEU's price volatile compared to industry and market?
NEU volatility
NEU Average Weekly Movement7.9%
Pharmaceuticals Industry Average Movement9.8%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market3.2%

Stable Share Price: NEU has not had significant price volatility in the past 3 months.

Volatility Over Time: NEU's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aJon Pilcherwww.neurenpharma.com

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes.

Neuren Pharmaceuticals Limited Fundamentals Summary

How do Neuren Pharmaceuticals's earnings and revenue compare to its market cap?
NEU fundamental statistics
Market capAU$2.40b
Earnings (TTM)AU$157.08m
Revenue (TTM)AU$231.94m

15.7x

P/E Ratio

10.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NEU income statement (TTM)
RevenueAU$231.94m
Cost of RevenueAU$26.75m
Gross ProfitAU$205.19m
Other ExpensesAU$48.11m
EarningsAU$157.08m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.23
Gross Margin88.47%
Net Profit Margin67.72%
Debt/Equity Ratio0%

How did NEU perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.